Stockreport

Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01

Evaxion Biotech A/S - American Depositary Share  (EVAX) 
PDF Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met primary endpoints for tolera [Read more]